Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells

被引：22

作者：

Munoz-Gamez, J. A. ^{[1
]}

Quiles-Perez, R. ^{[2
]}

Ruiz-Extremera, A. ^{[2
]}

Martin-Alvarez, A. B.

Sanjuan-Nunez, Laura ^{[3
]}

Carazo, A.

Leon, Josefa ^{[2
]}

Oliver, F. J. ^{[4
]}

Salmeron, J. ^{[2
]}

机构：

[1] San Cecilio Univ Hosp, Lab Med Res, Granada 18012, Spain

[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Granada, Spain

[3] Univ Granada, Dept Med, E-18071 Granada, Spain

[4] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain

来源：

CANCER LETTERS | 2011年 / 301卷 / 01期

关键词：

PARP-1; Antineoplastic therapy; Hepatocellular carcinoma; Transcriptional regulation; Cell death; DNA repair; HUMAN HEPATOCELLULAR-CARCINOMA; POLY(ADP-RIBOSE) POLYMERASE; GENE-EXPRESSION; PARP-1; DEFICIENCY; TUMOR; CARCINOGENESIS; MODULATION; ACTIVATION; GROWTH; INJURY;

D O I：

10.1016/j.canlet.2010.10.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The purpose of this study was to investigate whether PARP-1 inhibition sensitizes human liver cancer cell lines to doxorubicin treatment. Both the addition of PARP-1 inhibitor (ANI) and depletion by means of stable siRNA significantly enhanced the growth inhibition induced by the DNA damage agents used. This effect was associated with an accumulation of unrepaired DNA, with a reduction in EGER and Bcl-xL gene expression as well as with positive annexin-V staining. These results provide novel evidence of the direct role of PARP-1 in tumour chemoresistance in relation to its effects on the transcription of key genes involved in tumour survival. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：47 / 56

页数：10

共 37 条

[21]

Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane [J].

Nozaki, T ;

Fujihara, H ;

Watanabe, M ;

Tsutsumi, M ;

Nakamoto, K ;

Kusuoka, O ;

Kamada, N ;

Suzuki, H ;

Nakagama, H ;

Sugimura, T ;

Masutani, M .

CANCER SCIENCE, 2003, 94 (06) :497-500

[22]

Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice [J].

Ogawa, K ;

Masutani, M ;

Kato, K ;

Tang, MX ;

Kamada, N ;

Suzuki, H ;

Nakagama, H ;

Sugimura, T ;

Shirai, T .

CANCER LETTERS, 2006, 236 (01) :32-38

[23]

Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells [J].

Ogino, Hideki ;

Nozaki, Tadashige ;

Gunji, Akemi ;

Maeda, Miho ;

Suzuki, Hiroshi ;

Ohta, Tsutomu ;

Murakami, Yasufumi ;

Nakagama, Hitoshi ;

Sugimura, Takashi ;

Masutani, Mitsuko .

BMC GENOMICS, 2007, 8 (1)

[24]

Pacher P, 2006, INT J MOL MED, V17, P369

[25]

PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases [J].

Peralta-Leal, Andreina ;

Manuel Rodriguez-Vargas, Jose ;

Aguilar-Quesada, Rocio ;

Isabel Rodriguez, Maria ;

Luis Linares, Jose ;

Ruiz de Almodovar, Mariano ;

Javier Oliver, F. .

FREE RADICAL BIOLOGY AND MEDICINE, 2009, 47 (01) :13-26

[26]

Inhibition of Poly Adenosine Diphosphate-Ribose Polymerase Decreases Hepatocellular Carcinoma Growth by Modulation of Tumor-Related Gene Expression [J].

Quiles-Perez, Rosa ;

Antonio Munoz-Gamez, Jose ;

Ruiz-Extremera, Angeles ;

O'Valle, Francisco ;

Sanjuan-Nunez, Laura ;

Belen Martin-Alvarez, Ana ;

Martin-Oliva, David ;

Caballero, Trinidad ;

Munoz de Rueda, Paloma ;

Leon, Josefa ;

Gonzalez, Raul ;

Muntane, Jordi ;

Javier Oliver, Francisco ;

Salmeron, Javier .

HEPATOLOGY, 2010, 51 (01) :255-266

[27]

BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity [J].

Racz, I ;

Tory, K ;

Gallyas, F ;

Berente, Z ;

Osz, E ;

Jaszlits, L ;

Bernath, S ;

Sumegi, B ;

Rabloczky, G ;

Literati-Nagy, P .

BIOCHEMICAL PHARMACOLOGY, 2002, 63 (06) :1099-1111

[28]

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 [J].

Russo, Andrea L. ;

Kwon, Hyuk-Chan ;

Burgan, William E. ;

Carter, Donna ;

Beam, Katie ;

Weizheng, Xu ;

Zhang, Jie ;

Slusher, Barbara S. ;

Chakravarti, Arnab ;

Tofilon, Philip J. ;

Camphausen, Kevin .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :607-612

[29]

Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints [J].

Sabisz, Michal ;

Wesierska-Gadek, Jozefa ;

Skladanowski, Andrzej .

BIOCHEMICAL PHARMACOLOGY, 2010, 79 (10) :1387-1397

[30]

DNA vector-based RNAi approach for stable depletion of poly(ADP-ribose) polymerase-1 [J].

Shah, RG ;

Ghodgaonkar, MM ;

Affar, EB ;

Shah, GM .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (01) :167-174

← 1 2 3 4 →